A clot with cancer, in clinic: which anticoagulant for which tumor, and when apixaban can drop
Concepts first
- Cancer-associated clot
- Deep vein thrombosis or pulmonary embolism (venous thromboembolism) in a patient with active cancer: under treatment, recently diagnosed, or metastatic.
- Low molecular weight heparin
- Enoxaparin or dalteparin, injected under the skin once or twice a day. No gut absorption, few drug interactions. Dalteparin was the comparison arm in the four treatment trials below.
- Direct oral anticoagulant
- A pill that blocks one clotting factor: apixaban, rivaroxaban, edoxaban (factor Xa), dabigatran (thrombin).
- Luminal tumor
- A cancer with a surface inside a hollow organ: esophagus, stomach, colon, rectum, bladder, an unresected primary. It can ooze into the lumen.
- Major bleeding
- Fatal, in a critical site (brain, spine, eye, pericardium), or dropping hemoglobin by 2 g/dL or needing 2 or more units of blood (the international definition used in these trials).
- Clinically relevant bleeding
- Major bleeding plus bleeding that is not major but still needs a visit, a test, a dose change or a procedure.
- Treatment and extended phase
- Treatment: the first 6 months after the clot. Extended: anything after that, while the cancer is still active.
- Hazard ratio
- The event rate on one drug or dose divided by the other; under 1 favors the first. A subhazard ratio is the same, counting death as a competing event.
- Noninferior
- Shown to be not worse than the comparator by more than a preset margin.
Three pills against the same injection
Edoxaban, Hokusai VTE Cancer, 1,046 patients
6.9% vs 4.0%Major bleeding at 12 months against dalteparin. Fewer recurrent clots: 7.9% vs 11.3%. The excess bleeding was confined to gastrointestinal cancers, mostly upper gut.
Rivaroxaban, SELECT-D, 406 patients
13% vs 4%Clinically relevant non-major bleeding at 6 months, mostly gastrointestinal or urologic. Major bleeding 6% vs 4%. Fewer recurrent clots: 4% vs 11%.
Apixaban, Caravaggio, 1,155 patients
3.8% vs 4.0%Major bleeding at 6 months. Recurrent clots 5.6% vs 7.9%. Gastrointestinal cancers: 9 major bleeds in each arm.
The recurrence bars for all four cancer trials are on Oct 9, "A true failure". Here, the bleeding.
The worst case: esophageal and gastroesophageal cancer on rivaroxaban.Major bleeding 36% vs 11% with dalteparin. After an interim safety review of the first 220 patients, SELECT-D stopped enrolling these cancers (Young 2018, summarized in Ay 2019). In Hokusai, edoxaban added 7.9 percentage points of major bleeding in gastrointestinal cancer, and 71% of those bleeds were in the upper gut (Mulder 2020; Kraaijpoel 2018).
ADAM VTE, the smaller apixaban trial, 287 patients.Major bleeding 0% with apixaban and 1.4% with dalteparin; recurrent clots 0.7% vs 6.3% (McBane 2020).
Why the gut tumor matters
The mechanism is not proven.A high drug concentration in the gut lumen acting on the tumor or on chemotherapy-damaged mucosa is the explanation offered in the review literature (Ay 2019). The practical point stands without it: the excess bleeding sits where the tumor has a raw surface.
Pick the drug by the tumor
Apixaban or low molecular weight heparin.
Avoid edoxaban and rivaroxaban.
Apixaban was added to the American Society of Clinical Oncology guideline for treatment with a strong recommendation (Key 2023).
Platelets: the lines are 50,000 and 25,000.International guidance, all with low molecular weight heparin (Samuelson Bannow 2018, summarized in Xirou 2025):
50,000 or more: full dose, no transfusion.
25,000 to 50,000, high-risk clot (symptomatic proximal leg clot, pulmonary embolism): full dose with platelet transfusion to keep 40,000 to 50,000.
25,000 to 50,000, lower-risk clot (distal leg, subsegmental, catheter): half dose or prophylactic dose.
Under 25,000: hold; restart full dose above 50,000.
The pill trials did not test low counts.
The trap: 2.5 mg too early
Why people drop it early.For atrial fibrillation only, the US label lowers apixaban to 2.5 mg twice daily when 2 of 3 are present: age 80 or older, weight 60 kg or less, creatinine 1.5 mg/dL or more (the rule used in ARISTOTLE, Granger 2011). That rule belongs to stroke prevention, not to a fresh clot. In the cancer treatment trials, everyone got 10 mg twice daily for 7 days, then 5 mg twice daily (Agnelli 2020; McBane 2020).
API-CAT: what 2.5 mg did after 6 months
1,766 patients with active cancer who had already completed at least 6 months of anticoagulation (median 8 months from the clot), randomized, double blind, to apixaban 2.5 or 5 mg twice daily for 12 months (Mahé 2025).
Who bleeds in the extended phase, whatever the dose.Anemia or low platelets (subhazard ratio 1.93), age 75 or older (1.51), a pulmonary embolism as the first event (1.47), male sex (1.38) (Mahé 2026, post hoc).
The same pattern without cancer.AMPLIFY-EXT, after 6 to 12 months of treatment: recurrence 1.7% with apixaban 2.5 mg and 1.7% with 5 mg, against 8.8% with placebo (Agnelli 2013).
Decide at the bedside
The tumor picks the drug. The calendar picks the dose.
Check yourself
Question 1Gastric cancer, primary in place, new pulmonary embolism, platelets 180,000. Edoxaban?
No. Luminal upper gut tumor: edoxaban added major bleeding in gastrointestinal cancer, mostly upper gut. Apixaban or low molecular weight heparin.
Question 2Lung cancer, leg clot 5 weeks ago, apixaban 5 mg twice daily. Age 81, 58 kg. Someone writes "reduce to 2.5 mg". Do you?
No. Age and weight are the atrial fibrillation rule. For a clot, 2.5 mg was tested only after at least 6 months of full-dose treatment.
Question 3Colon cancer resected 2 years ago, now liver metastases on chemotherapy, clot 8 months ago, no recurrence, no bleeding. What dose now?
Cancer is active, so continue. Apixaban 2.5 mg twice daily matched 5 mg for recurrence and caused less clinically relevant bleeding in API-CAT.
Sources
Retrieved from PubMed and the US prescribing information, read on Nov 5, 2026.
- Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018. doi:10.1056/NEJMoa1711948
- Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer study. Thromb Haemost 2018. doi:10.1055/s-0038-1667001
- Mulder FI, van Es N, Kraaijpoel N, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE Cancer study. Thromb Res 2020;185:13-19. doi:10.1016/j.thromres.2019.11.007
- Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018. doi:10.1200/JCO.2018.78.8034
- Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer (Caravaggio). N Engl J Med 2020. doi:10.1056/NEJMoa1915103
- Ageno W, Vedovati MC, Cohen A, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021. doi:10.1055/s-0040-1720975
- McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020. doi:10.1111/jth.14662
- Mahé I, Carrier M, Mayeur D, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism (API-CAT). N Engl J Med 2025. doi:10.1056/NEJMoa2416112
- Mahé I, Chapelle C, Girard P, et al. Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial. Lancet Haematol 2026. doi:10.1016/S2352-3026(25)00291-1
- Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism (AMPLIFY-EXT). N Engl J Med 2013. doi:10.1056/NEJMoa1207541
- Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med 2011. doi:10.1056/NEJMoa1107039
- Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol 2019. doi:10.1093/annonc/mdz111
- Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018. doi:10.1111/jth.14015
- Xirou V, Patell R. STARTing to bridge the evidence gap: management of cancer-associated thrombosis with concomitant thrombocytopenia. Res Pract Thromb Haemost 2025;9:103165. doi:10.1016/j.rpth.2025.103165
- Apixaban (Eliquis) US prescribing information, section 2.2, dose adjustment in atrial fibrillation.
- Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023. doi:10.1200/JCO.23.00294
Oral iron done right: hepcidin sets the schedule
Workup and iron studies are on Oct 12 and Oct 21; intravenous products on Oct 7. This tab is only the pill.
Concepts first
- Hepcidin
- A liver hormone, the body's iron brake. It shuts ferroportin, the only door that lets iron out of gut cells into the blood (Camaschella 2015).
- What raises it
- Iron itself, and inflammation. What lowers it: iron deficiency and active red cell production.
- Fractional absorption
- The share of a dose that reaches the blood. It falls as the dose rises.
- Elemental iron
- The iron inside the salt. Doses below are elemental iron, as in the trials.
One dose closes the door for about a day
The dose that started it.Iron-depleted young women, labeled iron: 24 hours after a dose of 60 mg or more, hepcidin was up and absorption of the next dose fell 35 to 45%. Six times the dose (40 to 240 mg) gave only three times the iron absorbed (6.7 to 18.1 mg). An afternoon dose added no significant iron (Moretti 2015).
The trial: same 14 tablets, two calendars
What else shuts the door
The patient instruction in one line.One tablet every other morning with water, no tea, coffee, milk or calcium with it.
A high erythropoietin with low iron
The signal is working; the bricks are missing.In iron deficiency anemia, erythropoietin rises as hemoglobin falls, an appropriate response (Roque 2001). An erythropoiesis-stimulating agent adds more signal, not more iron, so it is not the fix. Give iron. When an erythropoietin level is low for the hemoglobin, think of the kidney (see Oct 12, erythropoietin).
Pill or vein
The 2-week check.Pooled oral iron arms of 5 trials: 72.8% rose 1 g/dL or more by day 14. That rise predicted a satisfactory response at 6 to 8 weeks with sensitivity 90.1% and specificity 79.3% (Okam 2017).
Check yourself
Question 1Ferrous sulfate three times a day, stomach pain, hemoglobin flat. First move?
One tablet every other morning. Three daily doses keep hepcidin up and absorb little more; fewer doses often fix the stomach too. Recheck the hemoglobin in 2 weeks.
Question 2Iron deficiency, on omeprazole for reflux, takes the tablet with breakfast coffee. What changes?
Coffee away from the tablet; try to stop or step down the proton pump inhibitor. If it must stay, or the 2-week hemoglobin rises less than 1 g/dL, intravenous iron.
Question 3Hemoglobin 8.4, ferritin 6, erythropoietin very high. Someone suggests an erythropoiesis-stimulating agent. Your answer?
No. The high erythropoietin is the normal answer to anemia; the marrow lacks iron, not signal. Replace iron and find the loss.
Sources
Retrieved from PubMed, read on Nov 5, 2026.
- Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015. doi:10.1182/blood-2015-05-642223
- Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017. doi:10.1016/S2352-3026(17)30182-5
- Camaschella C. Iron-deficiency anemia. N Engl J Med 2015. doi:10.1056/NEJMra1401038
- Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007. doi:10.1136/gut.2006.108613
- Morck TA, Lynch SR, Cook JD. Inhibition of food iron absorption by coffee. Am J Clin Nutr 1983. doi:10.1093/ajcn/37.3.416
- Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. Gut 1975. doi:10.1136/gut.16.3.193
- Hallberg L, Brune M, Erlandsson M, Sandberg AS, Rossander-Hultén L. Calcium: effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr 1991. doi:10.1093/ajcn/53.1.112
- Li N, Zhao G, Wu W, et al. The efficacy and safety of vitamin C for iron supplementation in adult patients with iron deficiency anemia: a randomized clinical trial. JAMA Netw Open 2020. doi:10.1001/jamanetworkopen.2020.23644
- Roque ME, Sandoval MJ, Aggio MC. Serum erythropoietin and its relation with soluble transferrin receptor in patients with different types of anaemia in a locally defined reference population. Clin Lab Haematol 2001. doi:10.1046/j.1365-2257.2001.00413.x
- Okam MM, Koch TA, Tran MH. Iron supplementation, response in iron-deficiency anemia: analysis of five trials. Am J Med 2017. doi:10.1016/j.amjmed.2017.03.045
- Pavord S, Daru J, Prasannan N, et al. UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol 2020. doi:10.1111/bjh.16221